Current State of Pediatric Cardio-Oncology: A Review
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/9/2/127 |
| _version_ | 1797481759010455552 |
|---|---|
| author | Molly Brickler Alexander Raskin Thomas D. Ryan |
| author_facet | Molly Brickler Alexander Raskin Thomas D. Ryan |
| author_sort | Molly Brickler |
| collection | DOAJ |
| description | The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients. |
| first_indexed | 2024-03-09T22:19:07Z |
| format | Article |
| id | doaj.art-50a16a0a4a47493bb33244d9648eaaad |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-09T22:19:07Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-50a16a0a4a47493bb33244d9648eaaad2023-11-23T19:17:52ZengMDPI AGChildren2227-90672022-01-019212710.3390/children9020127Current State of Pediatric Cardio-Oncology: A ReviewMolly Brickler0Alexander Raskin1Thomas D. Ryan2Children’s Wisconsin, Milwaukee, WI 53226, USAChildren’s Wisconsin, Milwaukee, WI 53226, USACincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USAThe landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients.https://www.mdpi.com/2227-9067/9/2/127cancercardio-oncologycardiovascularoncologypediatric |
| spellingShingle | Molly Brickler Alexander Raskin Thomas D. Ryan Current State of Pediatric Cardio-Oncology: A Review Children cancer cardio-oncology cardiovascular oncology pediatric |
| title | Current State of Pediatric Cardio-Oncology: A Review |
| title_full | Current State of Pediatric Cardio-Oncology: A Review |
| title_fullStr | Current State of Pediatric Cardio-Oncology: A Review |
| title_full_unstemmed | Current State of Pediatric Cardio-Oncology: A Review |
| title_short | Current State of Pediatric Cardio-Oncology: A Review |
| title_sort | current state of pediatric cardio oncology a review |
| topic | cancer cardio-oncology cardiovascular oncology pediatric |
| url | https://www.mdpi.com/2227-9067/9/2/127 |
| work_keys_str_mv | AT mollybrickler currentstateofpediatriccardiooncologyareview AT alexanderraskin currentstateofpediatriccardiooncologyareview AT thomasdryan currentstateofpediatriccardiooncologyareview |